BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 32649449)

  • 1. Sustained Elevation of Intraocular Pressure After Administration of Intravitreal Anti-Vascular Endothelial Growth Factor Agents in Patients With and Without Pseudoexfoliation Syndrome.
    Ucgul AY; Aktas Z; Ozgur A; Cubuk MO; Hasanreisoglu M; Ozdek S; Gurelik G
    J Glaucoma; 2020 Oct; 29(10):981-988. PubMed ID: 32649449
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect on intraocular pressure in patients receiving unilateral intravitreal anti-vascular endothelial growth factor injections.
    Hoang QV; Mendonca LS; Della Torre KE; Jung JJ; Tsuang AJ; Freund KB
    Ophthalmology; 2012 Feb; 119(2):321-6. PubMed ID: 22054994
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical predictors of sustained intraocular pressure elevation due to intravitreal anti-vascular endothelial growth factor therapy.
    Hoang QV; Tsuang AJ; Gelman R; Mendonca LS; Della Torre KE; Jung JJ; Freund KB
    Retina; 2013 Jan; 33(1):179-87. PubMed ID: 22990314
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sustained elevation of intraocular pressure after intravitreal injections of bevacizumab in eyes with neovascular age-related macular degeneration.
    Mathalone N; Arodi-Golan A; Sar S; Wolfson Y; Shalem M; Lavi I; Geyer O
    Graefes Arch Clin Exp Ophthalmol; 2012 Oct; 250(10):1435-40. PubMed ID: 22434210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EFFECT OF SERIAL ANTERIOR CHAMBER PARACENTESIS ON SUSTAINED INTRAOCULAR PRESSURE ELEVATION IN PATIENTS RECEIVING INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY.
    Sisk RA; Rusia D; Zamora BG; Kuley A; Toussaint BW
    Retina; 2019 Oct; 39(10):1959-1964. PubMed ID: 30234855
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sustained intraocular pressure elevation in eyes treated with intravitreal injections of anti-vascular endothelial growth factor for diabetic macular edema in a real-life setting.
    Vo Kim S; Fajnkuchen F; Sarda V; Qu-Knafo L; Bodaghi B; Giocanti-Aurégan A
    Graefes Arch Clin Exp Ophthalmol; 2017 Nov; 255(11):2165-2171. PubMed ID: 28831613
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Real-World Effect of Intravitreous Anti-Vascular Endothelial Growth Factor Drugs on Intraocular Pressure: An Analysis Using the IRIS Registry.
    Atchison EA; Wood KM; Mattox CG; Barry CN; Lum F; MacCumber MW
    Ophthalmology; 2018 May; 125(5):676-682. PubMed ID: 29336897
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A lack of delayed intraocular pressure elevation in patients treated with intravitreal injection of bevacizumab and ranibizumab.
    Wehrli SJ; Tawse K; Levin MH; Zaidi A; Pistilli M; Brucker AJ
    Retina; 2012 Jul; 32(7):1295-301. PubMed ID: 22466465
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term effects of intravitreal bevacizumab and aflibercept on intraocular pressure in wet age-related macular degeneration.
    Kähkönen M; Tuuminen R; Aaltonen V
    BMC Ophthalmol; 2021 Aug; 21(1):312. PubMed ID: 34454473
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glaucoma Tube Outcomes with and without Anti-VEGF in Patients with Age-related Macular Degeneration.
    Rothman AL; Beca FA; Tijerina JD; Schuman DM; Parrish RK; Vanner EA; Liu KC
    Ophthalmol Glaucoma; 2024; 7(3):260-270. PubMed ID: 38266962
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sustained increased intraocular pressure related to intravitreal antivascular endothelial growth factor therapy for neovascular age-related macular degeneration.
    Tseng JJ; Vance SK; Della Torre KE; Mendonca LS; Cooney MJ; Klancnik JM; Sorenson JA; Freund KB
    J Glaucoma; 2012; 21(4):241-7. PubMed ID: 21423038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intraocular Pressure Changes in Non-Glaucomatous Patients Receiving Intravitreal Anti-Vascular Endothelial Growth Factor Agents.
    Kiddee W; Montriwet M
    PLoS One; 2015; 10(9):e0137833. PubMed ID: 26360382
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intraocular Pressure in Patients with Neovascular Age-Related Macular Degeneration Receiving Intravitreal Aflibercept or Ranibizumab.
    Freund KB; Hoang QV; Saroj N; Thompson D
    Ophthalmology; 2015 Sep; 122(9):1802-10. PubMed ID: 26025097
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravitreal Anti-VEGF Injections Reduce Aqueous Outflow Facility in Patients With Neovascular Age-Related Macular Degeneration.
    Wen JC; Reina-Torres E; Sherwood JM; Challa P; Liu KC; Li G; Chang JY; Cousins SW; Schuman SG; Mettu PS; Stamer WD; Overby DR; Allingham RR
    Invest Ophthalmol Vis Sci; 2017 Mar; 58(3):1893-1898. PubMed ID: 28358961
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-Term Effect of Anti-VEGF Agents on Intraocular Pressure in Age-Related Macular Degeneration.
    Beato J; Pedrosa AC; Pinheiro-Costa J; Freitas-da-Costa P; Falcão MS; Melo A; Estrela-Silva S; Falcão-Reis F; Carneiro ÂM
    Ophthalmic Res; 2016; 56(1):30-4. PubMed ID: 27046391
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term effects of multiple intravitreal antivascular endothelial growth factor injections on intraocular pressure.
    Kim YJ; Sung KR; Lee KS; Joe SG; Lee JY; Kim JG; Yoon YH
    Am J Ophthalmol; 2014 Jun; 157(6):1266-1271.e1. PubMed ID: 24561173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intraocular pressure in eyes receiving monthly ranibizumab in 2 pivotal age-related macular degeneration clinical trials.
    Bakri SJ; Moshfeghi DM; Francom S; Rundle AC; Reshef DS; Lee PP; Schaeffer C; Rubio RG; Lai P
    Ophthalmology; 2014 May; 121(5):1102-8. PubMed ID: 24393349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term effect of intravitreal ranibizumab therapy on retinal nerve fiber layer in eyes with exudative age-related macular degeneration.
    Valverde-Megías A; Ruiz-Calvo A; Murciano-Cespedosa A; Hernández-Ruiz S; Martínez-de-la-Casa JM; García-Feijoo J
    Graefes Arch Clin Exp Ophthalmol; 2019 Jul; 257(7):1459-1466. PubMed ID: 31053943
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EFFICACY OF ADJUVANT TOPICAL DORZOLAMIDE-TIMOLOL IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION REFRACTORY TO ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY.
    Lee JH; Lee SC; Byeon SH; Koh HJ; Kim SS; Lee CS
    Retina; 2019 Oct; 39(10):1953-1958. PubMed ID: 30161096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Outcomes of Eyes with Submacular Hemorrhage Secondary to Age-related Macular Degeneration Treated with Anti-vascular Endothelial Growth Factor.
    Kim KH; Kim JH; Chang YS; Lee TG; Kim JW; Lew YJ
    Korean J Ophthalmol; 2015 Oct; 29(5):315-24. PubMed ID: 26457037
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.